The Multi-Trillion Dollar Opportunity in Reforming the FDA
Coverage of The Multi-Trillion Dollar Opportunity in Reforming the FDA in the Nexus archive.
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says
A new report claims delaying Food and Drug Administration (FDA) reviews costs trillions in economic value and slows access to lifesaving drugs. The report estimates cutting FDA effectiveness-review timelines by one year could generate over $10 trillion in economic value by accelerating treatments and innovation. Proposed reforms include faster clinical trials, greater use of artificial intelligence, and expanded 'right to try' programs.
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says
A new report claims that accelerating FDA drug approvals could generate over $10 trillion in economic value by reducing delays in effectiveness trials, which currently take about a decade. The report suggests reforms like AI in reviews and faster trials to boost competition and lower drug costs, while also addressing China's competitive threat in clinical trials.